Nitromed’s BiDil Should Not Be Second-Line Therapy, FDA Says
This article was originally published in The Pink Sheet Daily
BiDil should be indicated for first-line treatment of chronic heart failure in African American patients, FDA says in briefing material for the Cardiovascular & Renal Drugs Advisory Committee’s June 16 review of the Nitromed product. Nitromed had requested a second-line indication. BiDil would be the first drug specifically indicated for African Americans
You may also be interested in...
Company plans NDA resubmission by year-end with results from African American Heart Failure Trial in response to 2001 "approvable" letter for treatment of heart failure in African American patients. A-HeFT data show 43% survival improvement with BiDil vs. placebo.
The firm is planning for a first quarter 2005 launch after a trial in African American heart failure patients is halted early due to significant survival benefit. Initial positioning will be as an add-on to standard heart failure therapies. NitroMed sees a market opportunity of $1 bil.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications